A company can be worth more next year and still be a bad trade today. This is particularly easy to miss before an IPO, when the same company may have a funding-round valuation, an employee share price, and a derivatives market trading at three different numbers.
The useful question is not simply whether the business will grow. It is what your instrument pays if you are right, and how long you can afford to wait.
What the instrument pays
Buying shares, buying an interest in a vehicle that owns shares, and trading a contract linked to a company's valuation are different transactions. Shares can carry ownership rights. A vehicle adds its own fees and distribution rules. A derivative pays according to a reference price and contract terms; the company's name on the screen does not make it equity.
Actual private shares can also be difficult to transfer. An IPO may never happen, and a listing need not make every existing holder immediately free to sell. The SEC's pre-IPO investor alert explains why access to a recognizable private company is not enough to establish the quality or liquidity of an investment.
Comparing two valuations
Suppose a business raises $20 billion at a $200 billion post-money valuation. In this simplified example, the new money represents 10% of the business and the implied pre-money valuation is $180 billion. Comparing the $200 billion headline with an older $180 billion valuation and calling the difference pure appreciation would ignore the cash just contributed.
Next ask which shares the transaction priced. Imagine investors pay $100 million for preferred shares with a contractual first claim on $100 million of sale proceeds. If the company later sells for less than that, those shares can have a very different outcome from common shares. A headline valuation obtained by multiplying one class's price by every share assumes away that distinction.
A perpetual market quoting $230 billion against a $200 billion funding headline therefore has a 15% numerical premium. That is a starting observation, not proof of mispricing. The numbers may refer to different dates, share counts, rights, or definitions of value. For tokenized instruments, the SEC's staff statement on tokenized securities also distinguishes issuer-sponsored ownership from third-party arrangements that can create a different claim.
How a valuation reaches the contract
With listed shares, many buyers can compare the quoted price with an executable cash market. A private-company reference may instead depend on occasional financing rounds or a specified valuation methodology. Between updates, a derivative can move largely because traders change their expectations.
Read what happens at a financing, acquisition, IPO, or prolonged absence of new information. Does the contract settle, convert to another reference, or continue trading? Which source determines the value? Is the new share count included? These details determine whether your thesis and the contract are actually about the same outcome.
The cost of waiting
Consider a hypothetical $5,000 linear long position closed at a contract price 8% above its entry. Its gross gain is $400. If maintaining the position costs an average $4 a day, 60 days consume $240, leaving $160 before trading costs. At 100 days, the same $400 gain is entirely absorbed. Actual funding can change sign and size; a single day's rate is not a promise.
This gives an investment view two separate requirements: the eventual value must be attractive, and the route to realizing it must be affordable. A strong company can disappoint a buyer who paid too much. A correct valuation can disappoint a trader who paid to wait longer than expected.
The trade therefore needs more than a view on the company. It needs an event that reaches the contract’s reference price, at a value above the entry price, before the cost of waiting absorbs the difference.